Antidiabetic Combination Therapy

  • Henning Beck-Nielsen
  • Jan Erik Henriksen

Keywords: Type 2 diabetes, treatment, insulin, Metformin, sulfonylurea, glitazones, triple therapy, glycaemic control.


Triple Therapy Insulin Glargine Antidiabetic Drug Insulin Aspart Insulin Lispro 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stovring H, Andersen M, Beck-Nielsen H, et al. Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. Lancet 2003;362(9383):537–538.CrossRefPubMedGoogle Scholar
  2. 2.
    Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321(7258):405–412.CrossRefPubMedGoogle Scholar
  3. 3.
    Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45(7):S23–S28.PubMedGoogle Scholar
  4. 4.
    Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994;94(5):1714–1721.CrossRefPubMedGoogle Scholar
  5. 5.
    Turner RC, Holman RR, Cull CA, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837–853.CrossRefGoogle Scholar
  6. 6.
    Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281(21):2005–2012.CrossRefPubMedGoogle Scholar
  7. 7.
    Hother-Nielsen O, Beck-Nielsen H. On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3–3H-glucose infusion. Diabetologia 1990;33(10):603–610.CrossRefPubMedGoogle Scholar
  8. 8.
    Beck-Nielsen H, Hother-Nielsen O, Staehr P. Is hepatic glucose production increased in type 2 diabetes mellitus? Curr Diab Rep 2002; 2(3):231–236.CrossRefPubMedGoogle Scholar
  9. 9.
    Staehr P, Hother-Nielsen O, Beck-Nielsen H. The role of the liver in type 2 diabetes. Rev Endocr Metab Disord 2004;5(2):105–110.CrossRefPubMedGoogle Scholar
  10. 10.
    Beck-Nielsen H, Pedersen O, Sorensen NS. Effects of diet on the cellular insulin binding and the insulin sensitivity in young healthy subjects. Diabetologia 1978;15(4):289–296.CrossRefPubMedGoogle Scholar
  11. 11.
    Damsbo P, Vaag A, Hother-Nielsen O, et al. Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1991; 34(4):239–245.CrossRefPubMedGoogle Scholar
  12. 12.
    DeFronzo RA. Pathogenesis of type 2 (non-insulin- dependent) diabetes mellitus: a balanced overview. Diabetologia 1992;35(4):389–397.CrossRefPubMedGoogle Scholar
  13. 13.
    Ferrannini E, Gastaldelli A, Miyazaki Y, et al. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia 2003;46(9):1211–1219.CrossRefPubMedGoogle Scholar
  14. 14.
    Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23(5):583–588.CrossRefPubMedGoogle Scholar
  15. 15.
    Carey DG, Cowin GJ, Galloway GJ, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes Res 2002;10(10):1008–1015.CrossRefPubMedGoogle Scholar
  16. 16.
    DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333(9):541–549.CrossRefPubMedGoogle Scholar
  17. 17.
    Poulsen MK, Henriksen JE, Hother-Nielsen O, et al. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003; 26(12):3273–3279.CrossRefPubMedGoogle Scholar
  18. 18.
    Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000;320(7246):1373–1378.CrossRefPubMedGoogle Scholar
  19. 19.
    Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327(20):1426–1433.PubMedCrossRefGoogle Scholar
  20. 20.
    Strowig SM, Aviles-Santa ML, Raskin P. Improved glycemic weight control without gain using triple therapy in type 2 diabetes. Diabetes Care 2004; 27(7):1577–1583.CrossRefPubMedGoogle Scholar
  21. 21.
    Turner RC, Holman RR, Stratton IM, et al. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The UK Prospective Diabetes Study Group. Lancet 1998;352(9139):854.Google Scholar
  22. 22.
    Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17(6):467–473.CrossRefPubMedGoogle Scholar
  23. 23.
    Yki-Jarvinen H. Drug therapy: Thiazolidinediones. N Engl J Med 2004;351(11):1106–1118.CrossRefPubMedGoogle Scholar
  24. 24.
    Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23(8):1130–1136.CrossRefPubMedGoogle Scholar
  25. 25.
    Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):3080–3086.CrossRefPubMedGoogle Scholar
  26. 26.
    Goudswaard AN, Furlong NJ, Rutten GE, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004;(4):CD003418.Google Scholar
  27. 27.
    Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29(8):1963–1972.CrossRefPubMedGoogle Scholar
  28. 28.
    Roberts VL, Stewart J, Issa M, et al. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005;27(10):1535–1547.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Henning Beck-Nielsen
    • 1
  • Jan Erik Henriksen
    • 2
  1. 1.Department of EndocrinologyOdense University HospitalDenmark
  2. 2.Odense University HospitalDenmark

Personalised recommendations